Search the Newsreel

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan

Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 2,143 shares of Korro Bio common stock on August 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan …

Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock

Lynx1 Capital Management, a major shareholder in Korro Bio (NASDAQ:KRRO), recently acquired 1,462 shares for $19,283.78, increasing its stake to 1.54 million shares. This follows another purchase of 5,222 shares earlier in the month. Korro Bio's stock rose 1.8% to $13.59, and the company …

Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock

Lynx1 Capital Management Lp increased its stake in Korro Bio (NASDAQ:KRRO) by purchasing 5,222 shares for $59,530.80 and an additional 1,462 shares later. This brings their total holdings to 1.54 million shares. Korro Bio reported better-than-expected quarterly results with a loss of $1.07 per …

Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase

Korro Bio, Inc. (KRRO) reported that insider Lynx1 Capital Management LP and Weston Nichols indirectly purchased a total of 6,684 shares of common stock. These purchases occurred on August 6, 2026, at a weighted average price of $11.3998 per share (5,222 shares), and on …

Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Korro Bio Inc (KRRO) has an earnings forecast score of 8.20, ranking 159th in its industry, with an average analyst price target of $9.50. Analysts largely recommend a "Buy" for KRRO stock, with 11 analysts contributing to the rating. The company's expected revenue for …

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders

Korro Bio's stock recently climbed 28%, adding US$42 million to its market value, much to the satisfaction of insiders who had purchased shares in the last 12 months. One insider, Mohamad Makhzoumi, bought US$2.3 million worth of shares at a lower price than the …

Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS

Korro Bio Refines Capital Structure with Exchange Agreement

Korro Bio has refined its capital structure through an exchange agreement with Venrock Healthcare Capital Partners, reducing outstanding common shares while issuing pre-funded warrants. The company also reported progress on its pipeline, including an Orphan Drug Designation for KRRO-121 and the nomination of KRRO-111 …

Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22

Cantor Fitzgerald has reiterated its Buy rating for Korro Bio (KRRO.US) and maintained its target price at $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen

Wall Street Zen has upgraded Korro Bio (NASDAQ:KRRO) from "strong sell" to "sell," while the overall analyst consensus remains a "Moderate Buy" with a $16.71 price target. The company recently reported a quarterly loss of $1.07 per share, outperforming estimates, and revenue of $1.50 …

Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook

Raymond James has reiterated an Outperform rating and a $23.00 price target for Korro Bio Inc., based on the company's expansion into hyperammonemia indications. Korro Bio plans to initiate the first human clinical study for its lead asset, KRRO-121, in the second half of …

A Quick Look at Today's Ratings for Korro Bio(KRRO.US), With a Forecast Between $15 to $18

This article provides an overview of recent analyst ratings for Korro Bio (KRRO.US), showing a consensus analyst rating of "Buy" with an average price target of $16.50. The ratings are based on insights from three analysts, with individual price targets ranging from $15 to …

Korro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary

Korro Bio, Inc. reported no revenue for Q2 2026 due to a paused collaboration with Novo Nordisk, resulting in a net loss of $(18.9)M and diluted EPS of $(1.07). The company saw an improvement in net loss compared to the previous year, reallocated resources …

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Korro Bio, Inc. announced its second-quarter 2026 financial results, highlighting key advancements in its RNA editing programs. The company reported $137.9 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. Key developments include receiving Orphan …

Korro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price

Korro Bio (KRRO) entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026. Venrock surrendered 1,000,000 Korro shares, and in return, Korro issued pre-funded warrants to purchase 1,000,000 shares at a $0.001 exercise price. These warrants have no expiration, are …

Korro Bio (KRRO) CEO sells 5,802 shares of stock to cover taxes

Korro Bio's President and CEO, Ram Aiyar, sold 5,802 shares of common stock on August 4, 2026, at a weighted-average price of $10.844 per share. This sale was mandatory to cover tax withholding obligations on vested Restricted Stock Units (RSUs) under the company's 2023 …

Korro Bio (KRRO) Expected to Post Earnings on Tuesday

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Moderate Buy" from Analysts

Korro Bio, Inc. (NASDAQ:KRRO) has received a consensus "Moderate Buy" rating from twelve research firms, with an average 12-month price target of $16.71. Despite insider selling totaling approximately $4.31 million and recent quarterly EPS missing estimates, institutional investors have increased their positions in the …

Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Korro Bio Inc (KRRO), detailing its current price momentum score, support and resistance levels, and indicator readings. It also includes an analysis of various technical indicators like MACD, RSI, and moving averages, offering buy/sell signals for each. …

Korro Bio Inc (KRRO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Korro Bio Inc (KRRO), highlighting its current valuation score of 6.82, which ranks it 287 out of 384 in the Biotechnology & Medical Research industry. It notes that the company's P/E ratio is -0.86, being significantly below …

Korro Bio, Inc. Revenue Breakdown – NASDAQ:KRRO

Korro Bio, Inc. (NASDAQ: KRRO) generated $6.40 million USD in revenue last year. The majority of this revenue, $6.39 million USD, came from its RNA-editing Technology segment, significantly up from $2.27 million USD the previous year. The United States was the primary contributor, accounting …

Korro Bio Inc (KRRO) Cash Flow

The article provides a detailed cash flow statement for Korro Bio Inc (KRRO), including quarterly and annual data for operating, investing, and financing cash flows. It also defines key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free …

Korro Bio Inc (KRRO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Korro Bio Inc (KRRO). It notes that the company has distributed $0.00 in dividends over the past five years and lists several merger-related stock splits that occurred on November 3, 2023. The …

KRRO|Korro Bio Inc|Price:10.640|Chg%:-0.890

Korro Bio Inc. (KRRO) is a clinical-stage biopharmaceutical company focused on RNA editing. The stock is currently trading at $10.640, down 7.72% for the day. Analysts have a "Buy" rating with a target price of $19.556, despite the stock showing weak market performance over …

Korro Bio (KRRO) awards SVP 5,500 RSUs vesting through 2028

Korro Bio, Inc. (KRRO) Senior Vice President, Finance, Oliver Dolan, was granted 5,500 restricted stock units (RSUs) on July 15, 2026. These RSUs will vest in two tranches: 50% on July 15, 2027, and 50% on July 15, 2028, contingent on his continuous employment. …

Korro Bio (KRRO) grants 6,500 RSUs to General Counsel Jeffrey Cerio

Korro Bio, Inc. (KRRO) reported that its General Counsel, Jeffrey Cerio, was granted 6,500 restricted stock units (RSUs) on July 15, 2026. These RSUs will vest in two equal tranches on July 15, 2027, and July 15, 2028, subject to his continuous employment. Following …

Korro Bio (KRRO) CSO reports 25,797 shares after 7,500-share RSU grant

Korro Bio's Chief Scientific Officer, Vincent Loic A, reported an acquisition of 7,500 restricted stock units (RSUs) under the company's 2023 Stock Option and Incentive Plan. Following this grant, his direct ownership totals 25,797 shares, which includes 18,358 unvested RSU-based shares. The newly granted …

Form 4 Korro Bio Inc For: 17 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Korro Bio Inc, specifically dated July 17. The Form 4 is a U.S. Securities and Exchange Commission document which must be filed by company insiders when they trade shares in their own company. …

Korro Bio, Inc. (KRRO) awards 7,500 RSUs to Chief Operating Officer

Korro Bio, Inc. (KRRO) has awarded Chief Operating Officer Todd Chappell 7,500 restricted stock units (RSUs) under its 2023 Stock Option and Incentive Plan. These RSUs will vest 50% on July 15, 2027, and 50% on July 15, 2028, contingent on his continuous service. …

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

KRRO Q1 2026 Earnings: EPS Beat as Clinical Pipeline Progress Continues - Book Value Growth

KRRO Forecast — Price Target — Prediction for 2027